The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a sole source firm fixed-price contract to Illumina, Inc. for the preventative maintenance of MiSeq Sequencing Systems located in Bethesda, Maryland. This contract is crucial for ensuring the operational integrity of the equipment, which is essential for high-resolution Human Leukocyte Antigen (HLA) typing in transplant patient testing. Illumina, Inc. is the sole manufacturer and service provider for these systems, and their maintenance is necessary to prevent warranty invalidation and ensure accurate patient test results. Interested parties may express their interest by October 21, 2024, but the decision to not pursue competitive bids will be at the discretion of the government. For further inquiries, contact Emeka Onyejekwe at emeka.onyejekwe@nih.gov.